Inventor · disambiguated record
Lawrence Helson
Also filed as: HELSON LAWRENCE
24 granted patents·15 pending applications·301 citations·filing 1993–2020
96Inventor score
Files withSIGNPATH PHARMA INC25HELSON LAWRENCE4NAPRO BIOTHERAPEUTICS INC2UNIV NORTH TEXAS2UNIV TEXAS2
Top patents by PatentIndex Score
39 records- 0197US10117881B2Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathiesSIGNPATH PHARMA INC·Filed 2016·Granted Nov 6, 2018·16 cites·18 claims
- 0296US10449193B2Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathiesSIGNPATH PHARMA INC·Filed 2016·Granted Oct 22, 2019·13 cites·18 claims
- 0396US10238602B2Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathiesSIGNPATH PHARMA INC·Filed 2017·Granted Mar 26, 2019·16 cites·7 claims
- 0495US10357458B2Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier currentSIGNPATH PHARMA INC·Filed 2017·Granted Jul 23, 2019·16 cites·12 claims
- 0595US10349884B2Liposomal mitigation of drug-induced inhibition of the cardiac ikr channelSIGNPATH PHARMA INC·Filed 2017·Granted Jul 16, 2019·16 cites·20 claims
- 0694US9682041B2Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier currentSIGNPATH PHARMA INC·Filed 2014·Granted Jun 20, 2017·21 cites·14 claims
- 0794US8753674B2Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier currentHELSON LAWRENCE·Filed 2012·Granted Jun 17, 2014·29 cites·8 claims
- 0894US6667346B2Method for protecting cells and tissues from ionizing radiation toxicity with α, β unsaturated aryl sulfonesUNIV TEMPLE·Filed 2002·Granted Dec 23, 2003·71 cites·40 claims
- 0993US10617639B2Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier currentSIGNPATH PHARMA INC·Filed 2016·Granted Apr 14, 2020·5 cites·16 claims
- 1092US10258691B2Protective effect of DMPC, DMPG, DMPC/DMPG, EGPG, LysoPG and LysoPC against drugs that cause channelopathiesSIGNPATH PHARMA INC·Filed 2015·Granted Apr 16, 2019·16 cites·10 claims
- 1190US8747890B2Intravenous infusion of curcumin and a calcium channel blockerHELSON LAWRENCE·Filed 2010·Granted Jun 10, 2014·16 cites·2 claims
- 1285US10485768B2Treatment for glioblastomaSIGNPATH PHARMA INC·Filed 2016·Granted Nov 26, 2019·4 cites·7 claims
- 1383US10532045B2Liposomal mitigation of drug-induced inhibition of the cardiac IKr channelSIGNPATH PHARMA INC·Filed 2014·Granted Jan 14, 2020·6 cites·13 claims
- 1481US9138411B2Curcumin-ER, a liposomal-PLGA sustained release nanocurcumin for minimizing QT prolongation for cancer therapyUNIV NORTH TEXAS·Filed 2013·Granted Sep 22, 2015·12 cites·14 claims
- 1580US10004687B2Liposomal curcumin for treatment of diseasesUNIV TEXAS·Filed 2014·Granted Jun 26, 2018·4 cites·3 claims
- 1680US8784881B2Liposomal curcumin for treatment of diseasesKURZROCK RAZELLE·Filed 2007·Granted Jul 22, 2014·5 cites·3 claims
- 1772US7981928B2Chemotherapy method using x-raysNANODYNAMICS INC·Filed 2003·Granted Jul 19, 2011·2 cites·20 claims
- 1871US9170257B2Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcuminSIGNPATH PHARMA INC·Filed 2013·Granted Oct 27, 2015·1 cites·17 claims
- 1965US5696153ATherapeutic regimen for treating patientsNAPRO BIOTHERAPEUTICS INC·Filed 1996·Granted Dec 9, 1997·28 cites·12 claims
- 2065US2019321293A1Liposomal Mitigation of Drug-Induced Long QT Syndrome and Potassium Delayed-Rectifier CurrentSIGNPATH PHARMA INC·Filed 2019·Application pending·0 cites
- 2165US2019388422A1Protective effect of dmpc, dmpg, dmpc/dmpg, lysopg and lysopc against drugs that cause channelopathiesSIGNPATH PHARMA INC·Filed 2019·Application pending·0 cites
- 2264US2020108056A1Liposomal Mitigation of Drug-Induced Inhibition of the Cardiac IKR ChannelSIGNPATH PHARMA INC·Filed 2019·Application pending·0 cites
- 2363US2019167585A1Protective Effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC Against Drugs that Cause ChannelopathiesSIGNPATH PHARMA INC·Filed 2019·Application pending·0 cites
- 2459US2020046652A1Treatment for glioblastomaSIGNPATH PHARMA INC·Filed 2019·Application pending·0 cites
- 2555US2018318217A1Liposomal Curcumin for Treatment of DiseasesUNIV TEXAS·Filed 2018·Application pending·0 cites
- 2653US2014234402A1Intravenous Infusion of Curcumin and a Calcium Channel BlockerSIGNPATH PHARMA INC·Filed 2014·Application pending·0 cites
- 2750US2003149096A1Cancer chemopreventative compounds and compositions and methods of treating cancersFiled 2002·Application pending·0 cites
- 2848US12004868B2Liposomal mitigation of drug-induced inhibition of the cardiac IKr channelSIGNPATH PHARMA INC·Filed 2019·Granted Jun 11, 2024·0 cites·10 claims
- 2948US11806401B2Prevention of drug-induced atrio-ventricular blockSIGNPATH PHARMA INC·Filed 2017·Granted Nov 7, 2023·0 cites·5 claims
- 3046US2015147385A1Intravenous synthetic curcumin (s-curcumin) for the treatment of proliferative disordersSIGNPATH PHARMA INC·Filed 2014·Application pending·0 cites
- 3144US10739353B2Suppression of cytokine release and cytokine stormSIGNPATH PHARMA INC·Filed 2015·Granted Aug 11, 2020·0 cites·19 claims
- 3244US2020360300A1Suppression of Cytokine Release and Cytokine StormSIGNPATH PHARMA INC·Filed 2020·Application pending·0 cites
- 3343US2015377894A1Method and System for Measuring the Pharmacokinetics of Liposomal Curcumin and its Metabolite TetrahydrocurcuminSIGNPATH PHARMA INC·Filed 2015·Application pending·0 cites
- 3443US2015258026A1Curcumin-er, a liposomal-plga sustained release nanocurcumin for minimizing qt prolongation for cancer therapyUNIV NORTH TEXAS·Filed 2015·Application pending·0 cites
- 3540US2012237590A1Curcumin combination with anti-type 2 diabetic drugs for prevention and treatment of disease sequelae, drug-related adverse reactions, and improved glycemic controlHELSON LAWRENCE·Filed 2012·Application pending·0 cites
- 3639US2017252311A1Sphingosine kinase inhibitors and ceramide for maintenance therapy of glioblastomaSIGNPATH PHARMA INC·Filed 2017·Application pending·0 cites
- 3738US2016287532A1Curcumin for treating intervertebral disc diseaseSIGNPATH PHARMA INC·Filed 2016·Application pending·0 cites
- 3833US5688517AMethod for assessing sensitivity of tumor cells to cephalomannine and 10-deacetyltaxolNAPRO BIOTHERAPEUTICS INC·Filed 1993·Granted Nov 18, 1997·4 cites·15 claims
- 3932US9393198B2Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disordersHELSON LAWRENCE·Filed 2011·Granted Jul 19, 2016·0 cites·15 claims
Join the waitlist — get patent alerts
Get an alert when Lawrence Helson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →